{
    "clinical_study": {
        "@rank": "132793", 
        "arm_group": {
            "arm_group_label": "UX007", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "UX007-CL201 is an open-label Phase 2 study to assess the safety and clinical effects of\n      UX007 in subjects with LC-FAOD. Following a 4 week run in period on current therapy,\n      subjects will cross over to daily UX007 treatment for an initial 24 week treatment period,\n      followed by an additional 54 week extension period. Approximately 30 subjects between 6\n      months and 35 years of age inclusive with severe LC-FAOD, specifically VLCAD, LCHAD, CPT 2,\n      or TFP disorders, will be enrolled and treated with UX007."
        }, 
        "brief_title": "An Open-label Phase 2 Study of UX007 (Triheptanoin) in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)", 
            "Carnitine Palmitoyltransferase (CPT II) Deficiency", 
            "Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency", 
            "Longchain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency", 
            "Trifunctional Protein (TFP) Deficiency"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed diagnosis of CPT II, VLCAD, LCHAD, or TFP deficiency, based on results of\n             acylcarnitine profiles, fatty acid oxidation probe studies in cultured fibroblasts,\n             and/or mutation analysis obtained from medical records.\n\n          -  Male or female, 6 months - 35 years of age\n\n          -  Willing and able to complete all aspects of the study through the end of the study.\n             If a minor, have a caregiver(s) willing and able to assist in all applicable study\n             requirements.\n\n          -  Provide written informed consent (subjects aged \u2265 18 years), or provide written\n             assent (where appropriate) and have a legally authorized representative willing and\n             able to provide written informed consent\n\n          -  Willing and able to provide access to medical records charting the last 18-24 months\n             of care prior to the study initiation, or from birth for those subjects less than 18\n             months of age\n\n          -  No history of serious adverse reactions or known hypersensitivity to triheptanoin\n\n          -  Currently managed on a stable treatment regimen (including diet), which may include\n             low-fat/high-carbohydrate diet, avoidance of fasting, carnitine and/or MCT oil.  The\n             treatment regimen (including diet) should be stable for the last 60 days to assure\n             that changes in the subject's condition are not confounded by recent changes in the\n             treatment regimen that could affect the 4 week run-in evaluation period.  Once study\n             drug treatment has started, must be willing to maintain all aspects of the subject's\n             treatment regimen and diet unchanged, other than discontinuation of MCT oil, in order\n             to avoid potential variability of response due to variations in dietary intake.\n\n          -  Have severe LC-FAOD, as evidenced by ANY ONE of the following significant clinical\n             manifestations despite therapy:\n\n               -  Chronic Elevated CK with Major Clinical Events:  Elevated mean CK levels over\n                  the last 6 months -1 year (defined as \u2265 2X upper limit of age/gender-matched\n                  normal, or  \u2265 500  units/L if age-matched reference not established) not\n                  associated with an acute rhabdomyolysis event, AND at least two major clinical\n                  events (as defined in the protocol) in the last year, or at least four major\n                  clinical events over the last two years,\n\n               -  Episodic Elevated CK with Reported Muscle Dysfunction:  Episodes of elevated CK\n                  levels over the last 6 months -1 year (defined as \u2265 2X upper limit of\n                  age/gender-matched normal, or  \u2265 500  units/L if age-matched reference is not\n                  established) not associated with an acute rhabdomyolysis event, AND patient\n                  report of frequent muscle fatigue, exercise intolerance, or limitation of\n                  exercise,\n\n               -  Highly Elevated CK but Asymptomatic:  More seriously elevated mean CK levels\n                  (defined as \u2265 4X upper limit of age/gender-matched normal, or  \u2265 1000  units/L\n                  if age-matched reference is not established) consistent with substantial chronic\n                  muscle rupture over the last 6 months-1 year, regardless of frequency of\n                  hospitalizations or ER events,\n\n               -  Frequent Severe Major Medical Episodes (at least 3 within the past year, or 5\n                  within 2 years) of hypoglycemia, rhabdomyolysis, or exacerbation of CM,\n                  requiring ER/acute care visits or hospitalizations,\n\n               -  Severe Susceptibility to Hypoglycemia (serum glucose <60 mg/dL) after short\n                  periods of fasting (less than 4-12 hours, depending on age), with at least 2\n                  events in the last year that require ongoing prophylactic management, OR\n                  recurrent symptomatic hypoglycemia (blood glucose levels or clinical symptoms of\n                  hypoglycemia) at home requiring intervention \u2265 2 times per week,\n\n               -  Evidence of Functional Cardiomyopathy (with echocardiogram (ECHO) within past 90\n                  days documenting poor EF) requiring ongoing medical management\n\n          -  Females who have reached menarche must have a negative pregnancy test at Screening.\n             If sexually active, subject must be willing to use acceptable method of contraception\n             and have additional pregnancy tests during the study.\n\n        Exclusion Criteria:\n\n          -  Diagnosis of CACT or CPT I\n\n          -  Diagnosis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, short- or\n             medium-chain FAOD, ketone body metabolism defect, propionic acidemia or methylmalonic\n             acidemia\n\n          -  Enrolled in a clinical study involving concurrent use of an investigational drug\n             product within the last 30 days, or unwilling to discontinue use of a prohibited\n             medication or other substance that may confound study objectives\n\n          -  Unwilling to sign informed consent or release of medical records\n\n          -  Have any co-morbid conditions, including unstable major organ-system disease(s) that\n             in the opinion of the Investigator, places the subject at increased risk of\n             complications, interferes with study participation or compliance, or confounds study\n             objectives"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "35 Years", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01886378", 
            "org_study_id": "UX007-CL201"
        }, 
        "intervention": {
            "arm_group_label": "UX007", 
            "intervention_name": "UX007", 
            "intervention_type": "Drug", 
            "other_name": [
                "Triheptanoin", 
                "C7 oil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "FAOD", 
            "VLCAD", 
            "CPT II", 
            "CPT2", 
            "CPT 2", 
            "LCHAD", 
            "UX007", 
            "Triheptanoin", 
            "TFP"
        ], 
        "lastchanged_date": "March 10, 2014", 
        "location": [
            {
                "contact": {
                    "email": "lkehoe@childrensnational.org", 
                    "last_name": "Lindsay Kehoe", 
                    "phone": "202-476-4549"
                }, 
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20010"
                    }, 
                    "name": "Children's National Medical Center"
                }, 
                "investigator": {
                    "last_name": "Pranoot Tanpaiboon, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "dcasey1@health.usf.edu", 
                    "last_name": "Denise Casey", 
                    "phone": "813-259-8674"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33606"
                    }, 
                    "name": "University of Southern Florida"
                }, 
                "investigator": {
                    "last_name": "Amarilis Sanchez-Valle, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "CEdano@LurieChildrens.org", 
                    "last_name": "Clare Edano, MPH", 
                    "phone": "312-227-6129"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Ann & Robert H. Lurie Children's Hospital of Chicago"
                }, 
                "investigator": {
                    "last_name": "Barbara K Burton, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "vera.anastasoaie@childrens.harvard.edu", 
                    "last_name": "Vera Anastasoaie", 
                    "phone": "617-355-7346"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Boston Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Gerard Berry, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Elizabeth.Mccracken@chp.edu", 
                    "last_name": "Elizabeth McCracken, MS CGC", 
                    "phone": "412-692-5662"
                }, 
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15224"
                    }, 
                    "name": "Children's Hospital of Pittsburgh of UPMC"
                }, 
                "investigator": {
                    "last_name": "Gerard Vockley, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "natalie.n.owen@Vanderbilt.Edu", 
                    "last_name": "Natalie Owen", 
                    "phone": "615-322-7602"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt University Medical Center"
                }, 
                "investigator": {
                    "last_name": "John Phillips, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Carrie.Bailey@hsc.utah.edu", 
                    "last_name": "Carrie Bailey", 
                    "phone": "801-587-3605"
                }, 
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84132"
                    }, 
                    "name": "University of Utah"
                }, 
                "investigator": {
                    "last_name": "Nicola Longo, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Phase 2 Study to Assess Safety and Clinical Effects of UX007 in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)", 
        "other_outcome": {
            "description": "The impact of UX007 on major clinical events will be assessed by evaluating the change from baseline over 78 weeks of treatment of the number and duration of musculoskeletal, hepatic, and cardiac disease events caused by LC-FAOD, or intercurrent illness complicated by LC-FAOD, resulting in any hospitalization, ER visit, or emergency intervention (any unscheduled administration of therapeutics at home or in the clinic).", 
            "measure": "Evaluate the impact of UX007 on major clinical events associated with LC-FAOD (following 78 weeks of treatment)", 
            "safety_issue": "No", 
            "time_frame": "78 weeks"
        }, 
        "overall_contact": {
            "email": "kmooney@ultragenyx.com", 
            "last_name": "Kim Mooney", 
            "phone": "+1-415-483-8872"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The impact of UX007 on acute clinical pathophysiology associated with LC-FAOD will be assessed by evaluating the change from baseline over 24 weeks of treatment across the following 3 relevant disease areas: (1) skeletal myopathy: exercise intolerance measured by cycle ergometry, muscle weakness and fatigue, muscle function measured by the 12 Minute Walk Test (12MWT), motor development measured by the PDMS-2, functional disability, the number and duration of major rhabdomyolysis events, and non-CK levels; (2) hepatic disease: number of symptomatic or clinically important hypoglycemia events treated at home, number and duration of major hypoglycemia events, fasting serum glucose levels, liver size by hepatic ultrasound; and (3) cardiac disease: cardiac medication required for maintenance treatment, number and duration of major cardiomyopathy events, cardiomyopathy and cardiac function as measured by ECHO and ECG, and non-acute levels of BNP and troponin.", 
            "measure": "Evaluate the impact of UX007 on acute clinical pathophysiology associated with LC-FAOD (following 24 weeks of treatment)", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01886378"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The safety of UX007 treatment will be assessed based on the incidence rate of AEs, SAEs, and clinically significant changes in physical examination findings, vital signs, clinical laboratory parameters, ECHOs, ECGs, hepatic ultrasounds.", 
                "measure": "Evaluate the safety of UX007 treatment in subjects with LC-FAOD", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks and 78 weeks"
            }, 
            {
                "description": "The effect of UX007 on energy metabolism will be assessed by evaluating the change from baseline over 24 weeks and 78 weeks of treatment across biomarkers of UX007 effects, PK of UX007 and UX007 metabolites, LC-FAOD related laboratory parameters, and LC-FAOD laboratory parameters.", 
                "measure": "Evaluate the effect of UX007 on energy metabolism in LC-FAOD", 
                "safety_issue": "No", 
                "time_frame": "24 weeks and 78 weeks"
            }
        ], 
        "source": "Ultragenyx Pharmaceutical Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ultragenyx Pharmaceutical Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}